EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand

Hyperleukozytose und Zugang zu Minimaler Residualerkrankungs-(MRD-)Testung beeinflussen Outcomes bei Kindern mit neu diagnostizierter akuter myeloischer Leukämie in Thailand

Piya Rujkijyanont iD, Supak Ukritchon, Angkana Winaichatsak, Pitchayanan Kuwatjanakul, Thirachit Chotsampancharoen iD, Piti Techavichit iD, Su-On Chainansamit, Lalita Sathitsamitphong, Kittima Kanchanakamhaeng, Usanarat Anurathapan iD, Napat Laoaroon, Chonthida Wangkittikal und 9 weitere

Pediatric Blood & Cancer · 2026-03 · 73 (3)

DOI: 10.1002/1545-5017.70004 ↗

Auf einen Blick

Bei 282 Kindern mit neu diagnostizierter AML in Thailand waren 5-Jahres-Überleben und Rezidivrisiko ungünstig. Hohe initiale Leukozyten und der Zugang zu MRD-Testung waren mit schlechteren Outcomes assoziiert.

Fragestellung

Welche zusätzlichen Faktoren sind bei Kindern mit AML in Thailand mit Rezidiv und Tod assoziiert?

Methode

Retrospektive Auswertung von Daten von 282 Kindern mit neu diagnostizierter AML (2015–2019) in Thailand; Analyse von initialen Leukozyten, genetischer Analyse, postinduktiver MRD, Stammzelltransplantation und Supportivtherapie.

Ergebnisse

5-Jahres-Ereignisfreiheit 40,5 %, Gesamtüberleben 42,3 %, kumulative Rezidivinzidenz 47,4 %. Hohes Risiko: Tod aHR 1,8 (95 %-KI 1,1–2,9). MRD-Zugang: Tod aHR 1,7 (95 %-KI 1,1–2,5). WBC >100.000/mm3: Tod aHR 1,8 (95 %-KI 1,1–3,0), Rezidiv aHR 2,6 (95 %-KI 1,5–4,7).

Schlussfolgerung der Autor:innen

Erhöhte initiale Leukozytenzahlen und der Zugang zu MRD könnten zusätzliche Risikofaktoren für ungünstige Outcomes bei kindlicher AML sein.

Kernaussagen

  • 5-Jahres-Ereignisfreiheit: 40,5 %; Gesamtüberleben: 42,3 %
  • MRD-Zugang und hohes Risiko waren mit höherem Sterberisiko assoziiert
  • WBC >100.000/mm3 war mit Tod und Rezidiv assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 07.01.2026. Verfasst von Piya Rujkijyanont und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Pediatrics, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasm, Residual, Leukocytosis, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Thai Society of Hematology.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The survival outcomes among children with acute myeloid leukemia (AML) in low‐ and middle‐income countries are still poor despite adopting modern treatment regimens from developed countries. The study aimed to identify additional potential determinant factors for relapse and death among children with AML in Thailand.

Methods

In all, data from 282 children newly diagnosed with AML between 2015 and 2019 across Thailand were retrospectively reviewed. Data, including initial white blood cell numbers, genetic analysis, post‐induction minimal residual disease (MRD), hematopoietic stem cell transplantation, and supportive care, were analyzed.

Results

The probability of 5‐year, event‐free survival, overall survival, and cumulative incidence of relapse were 40.5%, 42.3%, and 47.4%, respectively. The risk of death was significantly increased among patients stratified as high‐risk AML with an adjusted hazard ratio (HR) of 1.8 (95% confidence interval [CI]: 1.1–2.9, p = 0.01). The accessibility to MRD was significantly associated with the risk of death with an adjusted HR of 1.7 (95% CI: 1.1–2.5, p = 0.01). Patients with low‐risk AML did carry a significant risk for both death, with an adjusted HR of 1.8 (95% CI: 1.1–3.0, p = 0.02), and relapse, with an adjusted HR of 2.6 (95% CI: 1.5–4.7, p < 0.001) for initial WBC greater than 100,000/mm 3 .

Conclusion

Elevated initial WBC numbers and accessibility to MRD could be considered additional risk factors for unfavorable outcomes in childhood AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteNeoplasm, ResidualLeukocytosisHematopoietic Stem Cell TransplantationHumansThailandFemaleChildMaleChild, PreschoolRetrospective StudiesInfantSurvival RateAdolescentPrognosisFollow-Up Studies

Stichwörter der Autor:innen

acute myeloid leukemiachildrenhyperleukocytosisrelapsesurvival outcome

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Pediatrics, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand.
  • Office of Research and Development, Phramongkutklao College of Medicine, Bangkok, Thailand.
  • Department of Pediatrics, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand.
  • Department of Pediatrics, Udon Thani Hospital, Udon Thani, Thailand.
  • Department of Pediatrics, Prince of Songkla University, Hat Yai, Thailand.
  • Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Center of Excellence in Pediatric Hematology/Oncology, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Piya Rujkijyanont, Thirachit Chotsampancharoen, Piti Techavichit, Usanarat Anurathapan, Chalinee Monsereenusorn, Jassada Buaboonnam, Samart Pakakasama

Förderung

  • Thai Society of Hematology

Zitieren

APA

Rujkijyanont, P., Ukritchon, S., Winaichatsak, A., Kuwatjanakul, P., Chotsampancharoen, T., Techavichit, P., Chainansamit, S. O., Sathitsamitphong, L., Kanchanakamhaeng, K., Anurathapan, U., Laoaroon, N., Wangkittikal, C., Monsereenusorn, C., Sanpote, W., Phalakornkul, N., Sripattanatadasakul, P., Isaranimitkul, D., Songkhla, P. N., Sinlapamongkolkul, P., …, & Pakakasama, S. (2026). Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand. Pediatric Blood & Cancer, 73(3). https://doi.org/10.1002/1545-5017.70004

Vancouver

Rujkijyanont P, Ukritchon S, Winaichatsak A, Kuwatjanakul P, Chotsampancharoen T, Techavichit P, et al. Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand. Pediatric Blood & Cancer. 2026;73(3). doi:10.1002/1545-5017.70004

BibTeX
@article{Rujkijyanont2026,
  author = {Rujkijyanont, Piya and Ukritchon, Supak and Winaichatsak, Angkana and Kuwatjanakul, Pitchayanan and Chotsampancharoen, Thirachit and Techavichit, Piti and Chainansamit, Su-On and Sathitsamitphong, Lalita and Kanchanakamhaeng, Kittima and Anurathapan, Usanarat and Laoaroon, Napat and Wangkittikal, Chonthida and Monsereenusorn, Chalinee and Sanpote, Watinee and Phalakornkul, Nattaporntira and Sripattanatadasakul, Pariwan and Isaranimitkul, Daranee and Songkhla, Pokpong Na and Sinlapamongkolkul, Phakatip and Buaboonnam, Jassada and Pakakasama, Samart},
  title = {Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {3},
  doi = {10.1002/1545-5017.70004}
}
Kostenlos starten →